Live feed08:00:00·309dPRReleasevia QuantisnowSepterna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven DiseasesByQuantisnow·Wall Street's wire, on your screen.SEPN· Septerna Inc.Health Care
